Allivictus Spray
Natural health product licensed in Canada
- Licence holder
- Allivictus Canada Ltd.
- NPN or DIN-HM
- 80042083
- Status
- Active licence
- Licence date
- 2 May 2013
- Revision date
- 3 February 2014
- Form
- Vaporisateur
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Allium sativum Source : Bulbe Extraction ratio : 1:1.667 Dry plant equivalent : 40.5 mg Potency : 40.5 mg | 67.5 % (p/v) | Not calculated |
Non-medicinal ingredients
Alcool
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes et adolescents | minimum: 14 years | minimum: 3 Pulvérisateur ; maximum: 4 Pulvérisateur | minimum: 5 Tous les jours ; maximum: 6 Tous les jours |
| Enfants et Adolescents | minimum: 2 years ; maximum: 14 years | minimum: 2 Pulvérisateur ; maximum: 3 Pulvérisateur | minimum: 3 Tous les jours ; maximum: 5 Tous les jours |
Uses authorised in Canada
Traditionally used in Herbal Medicine to help relieve the symptoms associated with upper respiratory tract infections and catarrhal conditions.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use if you are pregnant. Consult a health care practitioner prior to use if you have diabetes. Consult a health care practitioner prior to use if you are taking blood thinners or protease inhibitors.
- Effets indésirables connus
Hypersensitivity (e.g. allergy) has been known to occur; in which case discontinue use.
Source
Official Health Canada record, licence 80042083
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2014. Photograph the packaging to check whether it has changed. Photograph the packaging